Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

OPTIMA

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)

Currently recruiting

ORIGIN-1

ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)

Currently recruiting

AFMR_TTE

Outcomes of Surgery for Atrial Functional Mitral Regurgitation (ACTRN12624000705583)

Currently recruiting

PRO-DVd

Patient Reported Outcomes in patients received DVd for relapsed MM (ACTRN12618000659202)

No longer recruiting

PEPSTEP

Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)

Currently recruiting

MANTA

Percutaneous Decannulation of Extracorporeal Membrane Oxygenation Using MANTA Vascular Closure Device (ACTRN12621000791831)

Currently recruiting

PERSONAL

PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)

Currently recruiting

PFOX

PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)

Currently recruiting

SNDX-5613-0708

Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A [KMT2A/MLL], Nucleophosmin 1 [NPM1], and Nucleoporin 98 [NUP98] Genes (NCT06226571)

Coming soon

SLN124-004

Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)

Currently recruiting

diSArm Phage Therapy

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus (NCT05184764)

Currently recruiting

Tas-120-205

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements (NCT05727176)

Currently recruiting

MK-8591B 060

Phase 2 Study of ISL+ULO QW in Virologically Suppressed Adults With HIV-1 (NCT06891066)

Currently recruiting

TEBE-AM

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM) (NCT05549297)

Currently recruiting

AB-729-202

Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 in Virologically-Suppressed Chronic Hepatitis B Participants (ACTRN12622000317796)

Currently recruiting

ARTISTRY-2

Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® [Bictegravir/Emtricitabine/Tenofovir Alafenamide] in Virologically Suppressed People With HIV-1 [ARTISTRY 2] (NCT06333808)

Currently recruiting

GOLDEN GATE

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) (NCT04994717)

Currently recruiting

MajesTEC-4

Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) (NCT05243797)

Currently recruiting

C0371002

Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C =2%) (BeneGene-2) (NCT03861273)

No longer recruiting

AFFINE

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C<=1%) (NCT04370054)

No longer recruiting
24 25 26 27 28